---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-008531"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:57:57.552578+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro terminates ATM equity program after raising ~$1.3M at ~$1.20/share

## Summary
- Terminated ATM agreement with Ascendiant Capital Markets effective May 16, 2024.
- Sold 1,076,821 shares and raised approximately $1.3 million in gross proceeds (~$1.20 per share).
- Company cited limiting uncertainty and unfavorable dilution for stockholders as reason for termination.
- No further sales will be made under the ATM facility; all obligations cease upon termination.
- Clinical-stage biotech focused on Alzheimer's, bipolar, MDD, and PTSD treatments.

## SEC filing metadata
- accession: 0001214659-24-008531
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/0001214659-24-008531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/o572478k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-008531
- JSON: https://secwatch.observer/filing/0001214659-24-008531.json
- Plain text: https://secwatch.observer/filing/0001214659-24-008531.txt

## Key facts
- Material Agreements
  Alzamend Neuro, Inc. terminated Agreement with Ascendiant Capital Markets, LLC (effective 2024-05-16).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Ascendiant Capital Markets, LLC
  - Effective: 2024-05-16
  source text: Item 1.02 Termination of a Material Agreement On May 6, 2024, Alzamend Neuro, Inc. (the “ Company ”) provided written notice to Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) of its election to terminate the At-the-Market (“ ATM ”) Issuance Sales Agreement (the “ Agreement” ), dated September 8, 2023, between the Company and the Agent with regards to sales of the Company’s common stock under the Agreement. The Company had sold 1.08 million shares of common stock and raised approximately $1.3 million in gross proceeds, or approximately $1.20 per share, under the ATM. The termination is effective as of May 16, 2024. The material terms of the Agreement are summarized in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 8, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/0001214659-24-008531-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.